Literature DB >> 15540114

Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP.

K Watanabe1, K Okamoto, S Yonehara.   

Abstract

Fas-mediated apoptosis plays an important role in elimination of tumor cells in vivo, but some tumor-derived cells are resistant to this mechanism. Here, we show that treatment with the histone deacetylase (HDAC) inhibitor FR901228 renders Fas-resistant osteosarcoma cell lines sensitive to Fas-mediated apoptosis by downregulating expression of cellular FLIP (cellular FLICE-inhibitory protein), an inhibitor of Fas-mediated activation of caspase-8. Moreover, sensitization to Fas-mediated apoptosis was also induced in Fas-resistant osteosarcoma cells by suppressing FLIP expression using FLIP-specific RNA interference. HDAC inhibitors including FR901228 were shown to induce downregulation of cellular FLIP through inhibiting generation of FLIP mRNA, rather than stimulating degradation at either protein or mRNA level, and the inhibition was independent of de novo protein synthesis. These results clearly indicate that some tumor cells exhibit a phenotype resistant to death receptor-mediated apoptosis by expressing cellular FLIP, and that HDAC inhibitors sensitize such resistant tumor cells by directly downregulating cellular FLIP mRNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15540114     DOI: 10.1038/sj.cdd.4401507

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  31 in total

1.  Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.

Authors:  Nadezhda V Koshkina; Krithi Rao-Bindal; Eugenie S Kleinerman
Journal:  Cancer       Date:  2011-02-01       Impact factor: 6.860

2.  The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication.

Authors:  Angelika Danielsson; Helena Dzojic; Victoria Rashkova; Wing-Shing Cheng; Magnus Essand
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

Review 3.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

4.  The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.

Authors:  Krithi Rao-Bindal; Nadezhda V Koshkina; John Stewart; Eugenie S Kleinerman
Journal:  Curr Cancer Drug Targets       Date:  2013-05       Impact factor: 3.428

5.  Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model.

Authors:  C Blattmann; M Thiemann; A Stenzinger; A Christmann; E Roth; V Ehemann; J Debus; A E Kulozik; W Weichert; P E Huber; S Oertel; A Abdollahi
Journal:  Strahlenther Onkol       Date:  2013-06-27       Impact factor: 3.621

Review 6.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

7.  Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein.

Authors:  Yabing Chen; Jianmin Xu; Nirag Jhala; Pritish Pawar; Zeng B Zhu; Liping Ma; Chang-Hyun Byon; Jay M McDonald
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

8.  c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.

Authors:  John Kauh; Songqing Fan; Mingjing Xia; Ping Yue; Lily Yang; Fadlo R Khuri; Shi-Yong Sun
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

9.  PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells.

Authors:  Nilsa Rivera-Del Valle; Shan Gao; Claudia P Miller; Joy Fulbright; Carolina Gonzales; Mint Sirisawad; Susanne Steggerda; Jennifer Wheler; Sriram Balasubramanian; Joya Chandra
Journal:  Int J Cell Biol       Date:  2010-01-18

10.  The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation.

Authors:  Liying Wang; Neelam Azad; Lalana Kongkaneramit; Fei Chen; Yongju Lu; Bing-Hua Jiang; Yon Rojanasakul
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.